Rob van Maanen
Chief Tech/Sci/R&D Officer presso BIOPHYTIS S.A.
Patrimonio netto: 287 $ in data 31/03/2024
Profilo
Rob van Maanen is currently the Chief Medical Officer at Biophytis SA since 2021.
Prior to this, he worked as the Senior Director-Medical at Astellas BV and as the Chief Medical Officer at Khondrion BV.
He holds an MBA from the University of Amsterdam and a doctorate from the University of Utrecht.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
BIOPHYTIS SA
0.01% | 29/02/2024 | 75 983 ( 0.01% ) | 287 $ | 31/03/2024 |
Posizioni attive di Rob van Maanen
| Società | Posizione | Inizio |
|---|---|---|
| BIOPHYTIS S.A. | Chief Tech/Sci/R&D Officer | 09/09/2021 |
Precedenti posizioni note di Rob van Maanen
| Società | Posizione | Fine |
|---|---|---|
Astellas BV
 Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The private company is based in Leiden, Netherlands. | Chief Tech/Sci/R&D Officer | - |
Khondrion BV
 Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Chief Tech/Sci/R&D Officer | - |
Formazione di Rob van Maanen
| University of Amsterdam | Masters Business Admin |
| University of Utrecht | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BIOPHYTIS S.A. | Health Technology |
| Aziende private | 2 |
|---|---|
Astellas BV
Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The private company is based in Leiden, Netherlands. | Finance |
Khondrion BV
Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Health Technology |
- Borsa valori
- Insiders
- Rob van Maanen
